CABA Cabaletta Bio, Inc. Stock Quote

CABA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	3.30%	Shs Outstand	23.26M	Perf Week	-7.20%
Market Cap	320.53M	Forward P/E	-	EPS next Y	-2.11	Insider Trans	-45.25%	Shs Float	22.80M	Perf Month	-1.77%
Income	-29.40M	PEG	-	EPS next Q	-0.36	Inst Own	67.40%	Short Float	6.28%	Perf Quarter	6.60%
Sales	-	P/S	-	EPS this Y	-71.30%	Inst Trans	-1.72%	Short Ratio	15.42	Perf Half Y	-0.47%
Book/sh	5.05	P/B	2.53	EPS next Y	-51.10%	ROA	-22.40%	Target Price	20.33	Perf Year	-22.05%
Cash/sh	4.65	P/C	2.74	EPS next 5Y	-	ROE	-23.00%	52W Range	5.51 - 19.63	Perf YTD	2.24%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-35.00%	Beta	-
Dividend %	-	Quick Ratio	28.00	Sales past 5Y	-	Gross Margin	-	52W Low	131.58%	ATR	1.07
Employees	31	Current Ratio	28.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	44.78	Volatility	8.45% 7.49%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-75.00%	Profit Margin	-	Rel Volume	1.05	Prev Close	13.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	92.83K	Price	12.76
Recom	2.00	SMA20	-2.35%	SMA50	-7.84%	SMA200	16.58%	Volume	96,974	Change	-5.34%

Jan-08-21

Initiated

Chardan Capital Markets

Buy

$21

Oct-13-20

Initiated

H.C. Wainwright

Buy

$20

Nov-19-19

Initiated

Morgan Stanley

Overweight

$19

Nov-19-19

Initiated

Evercore ISI

Outperform

$25

Nov-19-19

Initiated

Cowen

Outperform

Jan-19-21 11:37PM	We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely Simply Wall St. +9.89%
Jan-07-21 08:00AM	Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-21 08:00AM	Cabaletta Bio to Participate in Upcoming January Investor Conferences GlobeNewswire
Dec-08-20 04:30PM	Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris GlobeNewswire
Dec-04-20 08:25AM	Is Cabaletta Bio (CABA) A Good Stock To Buy Now? Insider Monkey
Nov-23-20 08:00AM	Cabaletta Bio to Participate in Upcoming December Investor Conferences GlobeNewswire
Nov-10-20 07:30AM	Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc. - CABA ACCESSWIRE
Oct-22-20 07:39AM	What Kind Of Investors Own Most Of Cabaletta Bio, Inc. (NASDAQ:CABA)? Simply Wall St.
Sep-25-20 08:00AM	Cabaletta Bio to Present at Upcoming Investor Conferences in October GlobeNewswire +7.52%
Sep-08-20 08:00AM	Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences GlobeNewswire +7.87%
Aug-25-20 08:00AM	Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris GlobeNewswire
Aug-06-20 07:30AM	Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +6.63%
Aug-03-20 08:00AM	Cabaletta Bio to Present at Multiple August Investor Conferences GlobeNewswire +6.12%
Jul-24-20 07:42AM	We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely Simply Wall St.
Jul-07-20 08:00AM	Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies GlobeNewswire
Jun-24-20 04:25PM	Hedge Funds Keep Buying Cabaletta Bio, Inc. (CABA) Insider Monkey
Jun-01-20 12:00PM	Cabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
May-28-20 08:00AM	Cabaletta Bio Announces Expansion of Sponsored Research Agreement with the University of Pennsylvania GlobeNewswire
May-27-20 08:00AM	Cabaletta Bio to Present at Jefferies Virtual Healthcare Conference GlobeNewswire +8.92%
May-18-20 04:30PM	Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform GlobeNewswire
May-12-20 07:00AM	Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -9.79%
May-06-20 08:00AM	Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of Mucosal Pemphigus Vulgaris Business Wire
Apr-17-20 12:00PM	Cabaletta Bio, Inc. (CABA) Upgraded to Strong Buy: Here's What You Should Know Zacks
Mar-30-20 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update GlobeNewswire
Feb-20-20 08:00AM	Cabaletta Bio to Present at the Cowen and Company 40th Annual Health Care Conference GlobeNewswire
Jan-30-20 09:26AM	The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance Benzinga -8.30%
Jan-29-20 08:00AM	FDA Grants DSG3-CAART Orphan Drug Designation for the Treatment of Pemphigus Vulgaris GlobeNewswire +13.43%
Dec-23-19 04:32AM	3 Stocks with Growth Prospects in the Triple Digits TipRanks +33.86%
Nov-26-19 08:00AM	Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Oct-25-19 05:10PM	Phathom Pharmaceuticals Rises Almost 30% After $182 Million Bloomberg
07:36AM	Cabaletta Bio Announces Pricing of Initial Public Offering GlobeNewswire

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
5AM Ventures V, L.P.	10% Owner	Jan 12	Sale	13.00	85,000	1,105,000	369,688	Jan 12 05:07 PM
5AM Ventures V, L.P.	10% Owner	Jan 08	Sale	13.00	302,000	3,926,000	380,218	Jan 12 05:07 PM
5AM Ventures V, L.P.	10% Owner	Dec 10	Sale	14.75	298,000	4,395,500	417,629	Dec 14 05:58 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience